Global clinical trials, across all therapeutic areas, are projected to cost over £150 billion per annum by 2024. On average, the launch of each drug costs an estimated £2 billion. Trial costs continue to rise due to more complex drugs, increased complexity of trial methods and larger, multi-continent trials to achieve regulatory clearance. For Central Nervous System drugs, trial costs tend to be higher as they have a greater failure rate at a later stage especially when introducing first-in-class therapeutics with an unprecedented mode of action.